BamSEC and AlphaSense Join Forces
Learn More

Apogee Therapeutics Inc. – Material Contracts

NASDAQ: APGE    
Share price (3/27/26): $77.82    
Market cap (3/27/26): $5.407 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.29
from 10-K 3 pages Non-Employee Director Compensation Policy
12/34/56
EX-10.7
from 10-K 10 pages This Apogee Therapeutics, Inc. Executive Severance Policy (The “Policy”) Is Effective as of August 25, 2023 (The “Effective Date”). the Purpose of the Policy Is to Provide for the Payment of Severance Benefits to Certain Executives of Apogee Therapeutics, Inc. or One of Its Subsidiaries in Connection With a Termination of Employment in Certain Circumstances. 2. Definitions for Purposes of the Policy, the Terms Below Are Defined as Follows: (A) “Base Salary” Means the Annual Base Salary Payable to an Eligible Employee at the Time of the Termination Date
12/34/56
EX-10.1
from 10-Q 41 pages License Agreement
12/34/56
EX-10.3
from 10-Q 5 pages Fourth Amendment to License Agreement
12/34/56
EX-10.2
from 10-Q 6 pages [*] = Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted Because the Information (I) Is Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Samsung Biologics Co., Ltd. Product Specific Agreement – Product Drug Substance
12/34/56
EX-10.1
from 10-Q 39 pages [*] = Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted Because the Information (I) Is Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Master Services Agreement Between Samsung Biologics Co., Ltd. and Apogee Therapeutics, Inc. 1 [*] = Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted Because the Information (I) Is Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed
12/34/56
EX-10.5
from 10-Q 4 pages Third Amendment to License Agreement
12/34/56
EX-10.4
from 10-Q 3 pages Second Amendment to License Agreement
12/34/56
EX-10.3
from 10-Q 3 pages First Amendment to License Agreement
12/34/56
EX-10.2
from 10-Q 13 pages License Agreement
12/34/56
EX-10.1
from 10-Q 3 pages First Amendment to the Apogee Therapeutics, Inc. 2023 Employee Stock Purchase Plan [Signature Page Follows]
12/34/56
EX-10.6
from 10-K 7 pages Apogee Therapeutics, Inc. 2023 Equity Incentive Plan Grant Notice for Restricted Stock Unit Award
12/34/56
EX-10.7
from 10-Q 26 pages Antibody Discovery and Option Agreement
12/34/56
EX-10.9
from 10-Q 22 pages ​ Apogee Therapeutics, Inc. 2023 Equity Incentive Plan
12/34/56
EX-10.4
from 10-Q 8 pages Executive Employment Agreement
12/34/56
EX-10.3
from 10-Q 9 pages Executive Employment Agreement
12/34/56
EX-10.2
from 10-Q 9 pages Amended and Restated Executive Employment Agreement
12/34/56
EX-10.15
from S-1/A 16 pages Apogee Therapeutics, Inc. 2023 Employee Stock Purchase Plan
12/34/56
EX-10.14
from S-1/A 21 pages Apogee Therapeutics, Inc. 2023 Equity Incentive Plan
12/34/56
EX-10.15
from S-1/A 16 pages Apogee Therapeutics, Inc. 2023 Employee Stock Purchase Plan
12/34/56